University of Kiel   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Kiel Germany (1665)

Organization Overview

First Clinical Trial
2001
NCT00226473
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

ALL BFM study center Kiel, Germany | Christian-Albrechts-Universität zu Kiel, Klinik für Innere Medizin III Kardiologie, Angiologie und internistische Intensivmedizin, Kiel, Germany | Clinical Research Center Kiel | Clinical Research Center Kiel GmbH | Clinical Research Center Kiel GmbH, Germany | Coordinator Pathology (Germany) Department of Pathology Kiel | CRC Clinical Research Center Kiel | CRC Clinical Research Center, Kiel | Dept. of Dermatology, University of Kiel | Dept. of Dermatology, University of Kiel, Schittenhelmstrasse 5, D-24105 Kiel, Germany | Head of Unit of Neuropathic Pain Research and Therapy, Department of Neurology, University Clinic Kiel | Insitute of Human Nutrition, University of Kiel | Institute of Human Nutrition, Kiel University | Kiel Neurological Pain Centre | Klinik fur Dermatologie, Venerologie und Allerologie - Kiel - Germany | Medical Center II, University of Kiel, Germany | University Hospital Schleswig-Holstein - Campus Lübeck; Department of Gynecology & Obstetrics | University Hospital Schleswig-Holstein, Kiel | University of Kiel | University of Kiel, Arbeitsbereich Sportmedizin und Trainingswissenschaften

Active Ingredients

Drugs in Phase 4 Trials (6)

cisplatin (platinol) (2 trials)

dacarbazine (dtic-dome) (1 trial)

oxycodone (oxycontin) (1 trial)

phenprocoumon (liquamar) (1 trial)

tapentadol (nucynta) (1 trial)

vindesine (Eldisine) (1 trial)

Drugs in Phase 3 Trials (20)

adapalene (differin) (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

bortezomib (velcade) (1 trial)

carboplatin (paraplatin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

etoposide (vepesid) (2 trials)

fludarabine (fludara) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (1 trial)

irinotecan (Camptosar) (1 trial)

muromonab cd3 (Orthoclone OKT3) (1 trial)

nimotuzumab (2 trials)

oxaliplatin (eloxatin) (1 trial)

rituximab (rituxan) (1 trial)

sorafenib (nexavar) (1 trial)

thiotepa (1 trial)

treosulfan (1 trial)

urea (1 trial)

vincristine (oncovin) (1 trial)

Drugs in Phase 2 Trials (9)

allo-apz2-paod (1 trial)

dostarlimab (Jemperli) (1 trial)

niraparib (zejula) (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (1 trial)

pemetrexed (alimta) (1 trial)

rimabotulinumtoxinB (Myobloc) (1 trial)

tralokinumab (Adtralza) (1 trial)

wheat (1 trial)

Drugs in Other Trials (14)

apple (1 trial)

beta-hydroxybutyrate (1 trial)

carbamazepine (tegretol) (1 trial)

cellulose (1 trial)

cow milk (1 trial)

hesperidin (1 trial)

lacosamide (vimpat) (1 trial)

lactobacillus crispatus (1 trial)

lactobacillus gasseri (1 trial)

lactobacillus jensenii (1 trial)

lactobacillus rhamnosus (1 trial)

metronidazole (flagyl) (1 trial)

pimecrolimus (elidel) (1 trial)

vitamin c (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 3)

Arterial Occlusive Diseases (Phase 2)

Carcinoma, Hepatocellular (Phase 3)

Common Cold (Phase 2)

Communicable Diseases (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Fibromyalgia (Phase 2)

Glioblastoma (Phase 3)

Hemorrhage (Phase 4)

Hepatoblastoma (Phase 3)

Infections (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Melanoma (Phase 4)

Myofascial Pain Syndromes (Phase 2)

Neoplasm Metastasis (Phase 4)

Neuralgia (Phase 4)

Pancreatic Neoplasms (Phase 3)

Peripheral Arterial Disease (Phase 2)

Peripheral Nervous System Diseases (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Respiratory Tract Infections (Phase 2)

Somatoform Disorders (Phase 2)

Syndrome (Phase 2)

Thyroid Diseases (Phase 2)

Thyroid Neoplasms (Phase 2)

Waldenstrom Macroglobulinemia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial APIs: 49